Valentin Van de Walle
Lawyers
Filters
Ascentage Pharma $126.4 million IPO
The IPO is the first life sciences U.S. IPO of 2025 and the first life sciences company listed on the HKEX to complete a U.S. listing
Banco Santander $2 billion notes offering
We advised Banco Santander on the offering
Banco Santander $3.5 billion cash tender offers
We advised Banco Santander on its tender offers for fixed-rate notes
CRH $3 billion guaranteed notes offering
The investment-grade notes are due 2030, 2035 and 2055
Uranium Energy $300 million at-the-market offering
The shares are listed on NYSE American
Aker BP $1.5 billion notes offering
The notes are due 2034 and 2054
Norinchukin Bank $500 million senior notes offering
The senior notes are due 2029
NatWest Group $750 million contingent convertible Additional Tier 1 notes
We advised NatWest Group on the SEC-registered offering
Banco Santander renewal of $25 billion U.S. commercial paper program
We advised Banco Santander on its program renewal
Accenture $5 billion debut senior notes offering
The investment-grade notes are due 2027, 2029, 2031, and 2034